Corona Remedies' FY26 financial performance showed significant growth, with a 33.4% increase in profit after tax (PAT) to INR 199 crores, while total revenue reached INR 1,403 crores, a 17.3% year-on-year rise. The success can be attributed to the emphasis on chronic therapies and the expansion of biosimilars, resulting in two brands exceeding the INR 100 crore revenue mark.

Corona Remedies has announced a final dividend of INR 10 per share, giving shareholders a potential additional income.

Corona Remedies reports a significant 44% increase in Q4 profits, fueled by robust sales expansion. As a result of this success, the company has decided to pay out a ₹10 per share dividend for the fiscal year 2026.

Corona Remedies reported a 13% year-over-year increase in Q4 EBITDA, reaching ₹610 million, yet the margin slipped to 17.3% from 18.4%, indicating a 1.1 percentage point decline compared to last year.

Corona Remedies Limited reports a 24% increase in net profit for the fiscal year 2026, reaching Rs. 184.9 crore compared to Rs. 149.1 crore in the previous year. Shareholders may look forward to a proposed dividend of Rs. 10 per share, pending approval at the AGM, and the appointment of auditors for future years has also been announced.

Today, May 11, stocks like CMS Info Systems, Oberoi Realty, and Tata Consumer Products are under the spotlight, with anticipation for their upcoming Q4 financial results. On the other hand, Corona Remedies, UPL, Canara Bank, and Indian Hotels will be announcing their Q4 results for March 2026.

Corona Remedies' cash efficiency is robust, with an OCF to EBITDA ratio of 87%, suggesting they're effectively converting earnings into cash. The company hints at potential growth through more acquisitions, backed by their impressive financial statistics.

Corona Remedies anticipates significant growth of 20-25% annually for its product Wokadine within the next three years, setting ambitious expansion plans in motion.

Corona Remedies concludes 2022 with a cash reserve of INR 112 crores. The company aims to achieve a compound annual growth rate (CAGR) of 20-25% for its product Wpladone over the next three years.

Corona Remedies has purchased Wokadine from Dr. Reddy's, bolstering its position as the second player in India's Povidone Iodine market worth approximately 6.5 billion INR. The acquisition is self-funded using internal cash reserves.